# A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

> **NCT04408599** · PHASE1,PHASE2 · TERMINATED · sponsor: **NextCure, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Ovarian Cancer
- Gastric Cancer
- Colo-rectal Cancer

## Interventions

- **DRUG:** NC410

## Key facts

- **NCT ID:** NCT04408599
- **Lead sponsor:** NextCure, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-10
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors.
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04408599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04408599, "A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04408599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*